Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cloprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PTGFR | P43088 | 16/20 | 0.84 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.84 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.84 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cloprostenol SCHEMBL28077016 | 1.00 | ABCC4 (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Cloprostenol SCHEMBL29600088 | 1.00 | ABCC4 (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Cloprostenol SCHEMBL28242 | 1.00 | ABCC4 (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Cloprostenol SCHEMBL28850753 | 1.00 | ABCC4 (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Delprostenate SCHEMBL8206607 | 0.92 | ABCC4 (0.84) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Cloprostenol SCHEMBL17200671 | 0.92 | PTGFR (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Cloprostenol SCHEMBL15390430 | 0.92 | PTGFR (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Cloprostenol SCHEMBL123595 | 0.92 | PTGFR (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Cloprostenol SCHEMBL123596 | 0.92 | PTGFR (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 | |
| Cloprostenol SCHEMBL14913508 | 0.92 | PTGFR (1.00) | ABCC4PTGFRPTGER3TBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929340-B | Methods and agents for glaucoma | 奥夫博医疗创新有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20240358799-A1 | METHODS AND COMPOSITIONS FOR REPRODUCTIVE MANAGEMENT OF SHEEP AND GOATS | REPROLOGIX (US) | 2024-10-31 | — | — | US | disclosed |
| CN-113164043-B | Compositions and methods for glaucoma | 奥夫博医疗创新有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024015308-A1 | REMOVABLE TREATMENT MANAGEMENT APPARATUS AND TREATMENT MANAGEMENT SYSTEM | PARNELL TECHNOLOGIES PTY. LTD. (AU) | 2024-01-18 | — | — | WO | disclosed |
| US-20240013884-A1 | REMOVABLE TREATMENT MANAGEMENT APPARATUS AND TREATMENT MANAGEMENT SYSTEM | PARNELL TECH PTY LTD (AU) | 2024-01-11 | — | — | US | disclosed |
| US-20240000849-A1 | MICROFLUIDIC DEVICE FOR ISOLATING COMPONENTS OF BODILY FLUIDS | UNIV CORNELL (US) | 2024-01-04 | — | — | US | disclosed |
| US-11752175-B2 | Compositions and methods for glaucoma | CORNELL UNIVERSITY (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023027950-A1 | METHODS FOR REPRODUCTIVE MANAGEMENT OF SHEEP AND GOATS | REPROLOGIX (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-4031244-A1 | PROCESSES AND AGENTS FOR GLAUCOMA | Aufbau Medical Innovations Limited (IE) | 2022-07-27 | — | — | EP | disclosed |
| US-20220211800-A1 | PROCESSES AND AGENTS FOR GLAUCOMA | CORNELL UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211800-A1 | PROCESSES AND AGENTS FOR GLAUCOMA | RHOA, PDE6C, EXOSC10 | THRB 4770/4885ABCC4 424/4885PTGFR 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.